Folate pathway gene polymorphisms and risk of childhood brain tumors: results from an Australian case-control study.

Autor:	Greenop KR; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., Scott RJ; Hunter Medical Research Institute, John Hunter Hospital, New South Wales, Australia. School of Biomedical Sciences and Pharmacy, Faculty of Health, University of Newcastle, Newcastle, New South Wales, Australia. Hunter Area Pathology Service, HNEHealth, Newcastle, New South Wales, Australia., Attia J; Hunter Medical Research Institute, John Hunter Hospital, New South Wales, Australia. School of Medicine and Public Health, Faculty of Health and Medicine, University of Newcastle, Newcastle, New South Wales, Australia., Bower C; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., de Klerk NH; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., Norris MD; Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia., Haber M; Children's Cancer Institute Australia for Medical Research, Lowy Cancer Research Centre, University of New South Wales, Sydney, New South Wales, Australia., Jamieson SE; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia., van Bockxmeer FM; School of Surgery, University of Western Australia, Perth, Western Australia, Australia. Department of Clinical Biochemistry, Royal Perth Hospital, Perth, Western Australia, Australia., Gottardo NG; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia. School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia. Department of Paediatric Oncology/Haematology, Princess Margaret Hospital for Children, Perth, Western Australia, Australia., Ashton LJ; Research Portfolio, University of Sydney, Sydney, Australia. School of Women's and Children's Health, Faculty of Medicine, University of New South Wales, Sydney, Australia., Armstrong BK; Sax Institute, Haymarket, New South Wales, Australia. Sydney School of Public Health, University of Sydney, New South Wales, Australia., Milne E; Telethon Kids Institute, University of Western Australia, Perth, Western Australia, Australia. Liz.Milne@telethonkids.org.au.
Jazyk:	angličtina
Zdroj:	Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology [Cancer Epidemiol Biomarkers Prev] 2015 Jun; Vol. 24 (6), pp. 931-7. Date of Electronic Publication: 2015 Mar 25.
DOI:	10.1158/1055-9965.EPI-14-1248
Abstrakt:	Background: Recent research suggests that maternal folic acid supplementation is associated with a reduced risk of childhood brain tumors (CBT); polymorphisms in folate pathway genes could modify this association or directly influence CBT risk. Methods: Associations between risk of CBT and folate pathway polymorphisms were investigated in a population-based case-control study in Australia (2005-2010). Cases were recruited through all Australian pediatric oncology centers and controls by national random digit dialing. Data were available from 321 cases and 552 controls. Six polymorphisms were genotyped in children and parents (MTHFR 677C>T, MTHFR 1298A>C, MTRR 66A>G, MTR 2756A>G, MTR 5049C>A, and CBS 2199 T>C). Maternal folic acid use was ascertained via questionnaire. ORs were estimated using unconditional logistic regression. Case-parent trio analyses were also undertaken. Results: There was weak evidence of a reduced risk of CBT for the MTRR 66GG genotype in the child or father: ORs 0.71 [95% confidence interval (CI), 0.48-1.07]; 0.54 (95% CI, 0.34-0.87), respectively. Maternal prepregnancy folic acid supplementation showed a stronger negative association with CBT risk where the child, mother, or father had the MTRR 66GG genotype (Pinteraction = 0.07, 0.10, and 0.18, respectively). Conclusions: Evidence for an association between folate pathway genotypes and CBT is limited in this study. There was possible protection by the MTRR 66GG genotype, particularly when combined with maternal prepregnancy folic acid supplementation; these results are novel and require replication. Impact: The possible interaction between folic acid supplementation and MTRR 66A>G, if confirmed, would strengthen evidence for prepregnancy folate protection against CBT. (©2015 American Association for Cancer Research.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu